Abstract | OBJECTIVE: METHODS: Anti- topo I antibody levels were determined by enzyme-linked immunosorbent assay. In a longitudinal study, 125 sera from 21 patients were analysed during a follow-up period of 0.2-4.7 yr. RESULTS: Anti- topo I antibody levels were correlated positively with skin thickness score and renal vascular resistance, and inversely with percentage vital capacity. In the longitudinal study, five patients with a low anti- topo I antibody level at their first visit exhibited a stable antibody level or a small decrease in the level during the follow-up period, and their skin sclerosis was stable. Of 16 patients with a high anti- topo I antibody level at their first visit, seven showed a stable level, four had an increasing level and five had a decreasing level. The decreasing levels were accompanied mainly by atrophic skin change during the follow-up period, whereas the increasing levels were associated with new onset or worsening of organ involvement. CONCLUSIONS: These results suggest the potential clinical significance of anti- topo I antibody levels in evaluating disease severity and the prognosis in SSc.
|
Authors | S Sato, Y Hamaguchi, M Hasegawa, K Takehara |
Journal | Rheumatology (Oxford, England)
(Rheumatology (Oxford))
Vol. 40
Issue 10
Pg. 1135-40
(Oct 2001)
ISSN: 1462-0324 [Print] England |
PMID | 11600743
(Publication Type: Journal Article)
|
Chemical References |
- Autoantibodies
- DNA Topoisomerases, Type I
|
Topics |
- Adolescent
- Adult
- Aged
- Autoantibodies
(blood)
- Child
- Child, Preschool
- DNA Topoisomerases, Type I
(immunology)
- Enzyme-Linked Immunosorbent Assay
- Female
- Humans
- Longitudinal Studies
- Male
- Middle Aged
- Predictive Value of Tests
- Scleroderma, Systemic
(immunology, pathology)
- Severity of Illness Index
- Skin
(pathology)
|